(Q47995950)

7 February 2018

title

Intrathecal activation of the complement system and disability in multiple sclerosis (English)

1 reference

7 February 2018

0 references

Sellebjerg F

1

1 reference

7 February 2018

Jaliashvili I

series ordinal

2

1 reference

7 February 2018

Christiansen M

series ordinal

3

1 reference

7 February 2018

Garred P

series ordinal

4

1 reference

7 February 2018

publication date

1 May 1998

1 reference

7 February 2018

Journal of the Neurological Sciences

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

7 February 2018

volume

157

1 reference

7 February 2018

issue

2

1 reference

7 February 2018

page(s)

168-174

1 reference

7 February 2018

Functions and relevance of the terminal complement sequence

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Immunocytochemical localization of the terminal complement complex in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Optic neuritis and multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Protein size and cerebrospinal fluid composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

MRI, VEP, SEP and biothesiometry suggest monosymptomatic acute optic neuritis to be a first manifestation of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Quantification in Enzyme-Linked Immunosorbent Assay of a C3 Neoepitope Expressed on Activated Human Complement Factor C3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Characterization of a Monoclonal Antibody MoAb bH6 Reacting with a Neoepitope of Human C3 Expressed on C3b, iC3b, and C3c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Defining the clinical course of multiple sclerosis: Results of an international survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Inhibition of Complement-Mediated Red Cell Lysis by Immunoglobulins is Dependent on the IG Isotype and its Cl Binding Properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Expression of complement in the brain: role in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Qualitative assessment of intrathecal IgG synthesis by isoelectric focusing and immunodetection: interlaboratory reproducibility and interobserver agreement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900086-0

10.1016/S0022-510X(98)00086-0

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

release_trmc2nn7nff5vjqrv6zg6nshzi

Fatcat ID

0 references

1 reference

7 February 2018